We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
Cap. Flow
+$1.13B
Cap. Flow %
11.96%
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$51.9M
2
MRK icon
Merck
MRK
+$50.9M
3
DHR icon
Danaher
DHR
+$45.3M
4
TMO icon
Thermo Fisher Scientific
TMO
+$37.8M
5
JD icon
JD.com
JD
+$37.7M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$103M
2
BABA icon
Alibaba
BABA
+$98.6M
3
CRM icon
Salesforce
CRM
+$62.5M
4
BMY icon
Bristol-Myers Squibb
BMY
+$59.4M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 34.61%
2 Technology 20.94%
3 Consumer Discretionary 8.9%
4 Financials 8.59%
5 Communication Services 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHP icon
751
BHP
BHP
$213B
$3K ﹤0.01%
76
+5
+7% +$196
HMC icon
752
Honda
HMC
$39.3B
$3K ﹤0.01%
114
+33
+41% +$802
ACN icon
753
Accenture
ACN
$101B
$2K ﹤0.01%
7
– –
APTV icon
754
Aptiv
APTV
$12.6B
$2K ﹤0.01%
30
+6
+25% +$413
CRH icon
755
CRH
CRH
$69.1B
$2K ﹤0.01%
66
+26
+65% +$802
ETN icon
756
Eaton
ETN
$150B
$2K ﹤0.01%
22
-1
-4% -$82
MDT icon
757
Medtronic
MDT
$111B
$2K ﹤0.01%
26
+12
+86% +$1.15K
TEF
758
DELISTED
Telefonica
TEF
$2K ﹤0.01%
611
+26
+4% +$101
TT icon
759
Trane Technologies
TT
$104B
$2K ﹤0.01%
24
-6
-20% -$522
CHRW icon
760
C.H. Robinson
CHRW
$20B
$1K ﹤0.01%
+11
New +$830
CYBR
761
DELISTED
CyberArk
CYBR
$1K ﹤0.01%
10
– –
EQNR icon
762
Equinor
EQNR
$90.9B
$1K ﹤0.01%
77
-82
-52% -$1.15K
GSK icon
763
GSK
GSK
$108B
$1K ﹤0.01%
+14
New +$718
HSBC icon
764
HSBC
HSBC
$356B
$1K ﹤0.01%
41
-27
-40% -$670
JAZZ icon
765
Jazz Pharmaceuticals
JAZZ
$16.1B
$1K ﹤0.01%
+10
New +$1.11K
NVCR icon
766
NovoCure
NVCR
$1.89B
$1K ﹤0.01%
9
+1
+13% +$66
SONY icon
767
Sony
SONY
$133B
$1K ﹤0.01%
85
– –
VOD icon
768
Vodafone
VOD
$37.7B
$1K ﹤0.01%
+36
New +$543
VTRS icon
769
Viatris
VTRS
$20.8B
$1K ﹤0.01%
50
– –
WBK
770
DELISTED
Westpac Banking Corporation
WBK
$1K ﹤0.01%
93
+6
+7% +$66
ACB
771
Aurora Cannabis
ACB
$168M
– –
-337
Closed -$85K
AIV
772
Aimco
AIV
$375M
– –
-56,459
Closed -$380K
ALK icon
773
Alaska Air
ALK
$5.42B
– –
-95,796
Closed -$6.34M
AMX icon
774
America Movil
AMX
$77.2B
– –
-21,550
Closed -$337K
ANAB icon
775
AnaptysBio
ANAB
$1.54B
– –
-115,000
Closed -$1.83M
29 30
31
32 33

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2020 Portfolio in Review

As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.

  • Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
  • Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
  • Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
  • Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
  • Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
  • Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
  • Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.

Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.